AI assistant
Olema Pharmaceuticals, Inc. — Director's Dealing 2021
Jun 22, 2021
32591_dirs_2021-06-21_07e9ec72-6540-48bc-a14c-ab9bade46133.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Olema Pharmaceuticals, Inc. (OLMA)
CIK: 0001750284
Period of Report: 2021-06-18
Reporting Person: Harmon Cyrus (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-18 | Common Stock | S | 9410 | $24.54 | Disposed | 1102136 | Direct |
| 2021-06-18 | Common Stock | S | 1990 | $25.59 | Disposed | 1100146 | Direct |
| 2021-06-18 | Common Stock | S | 600 | $26.30 | Disposed | 1099546 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2: The weighted average sale price for the transaction reported was $24.54, and the range of prices were between $24.18 and $25.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The weighted average sale price for the transaction reported was $25.59, and the range of prices were between $25.16 and $26.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4: 2. The weighted average sale price for the transaction reported was $26.30, and the range of prices were between $26.19 and $26.99. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.